Anti-Jc Virus Antibody Sera Positivity and Index Value Among Patients With Multiple Sclerosis May Be Correlated With Age, Sex, and Area of Residence Publisher Pubmed



Koolaji S¹ ; Allahabadi NS¹ ; Ahmadi A¹ ; Eskandarieh S^{1, 2} ; Moghadasi AN¹ ; Azimi AR¹ ; Sahraian MA¹ Show Affiliations
Source: Journal of NeuroVirology Published:2018

Abstract

Anti-JC virus (JCV) antibody index is the predictive factor of progressive multifocal leukoencephalopathy (PML) for multiple sclerosis (MS) patients treating with natalizumab. The aim of this study is to evaluate the prevalence of anti-JCV antibody positivity and index among Iranian patients who are the candidate for natalizumab and its correlation with their demographic data and previous therapies. A cross-sectional design was assessed for receiving anti-JCV antibody test results between January 2014 and December 2016. Demographic data and disease characteristics were also obtained. Statistical analysis and logistic regression were done using SPSS. Among 803 MS patients that were observed, the prevalence of anti-JCV antibody positivity was 67.9% (mean of index = 2.23 ± 1.16) and 67.6% of positive patients had an index ≥ 1.5. Males were more antibody positive than females (81.7 and 64% respectively; significance (sig.) < 0.001, OR = 2.51, CI 1.65–3.81). The rate of positivity was lower in patients under the age of 18. Patients who lived in cold regions had significantly more prevalence of positivity (Num. = 403; sig. = 0.043 and OR = 1.86; CI 1.02–3.39) and with higher rate of index ≥ 1.5 (sig. = 0.017; OR = 3.99, CI 1.79–8.88). Disease onset age between 28 and 37 years were more positive compared to 18–27 years (N = 480; sig. = 0.02; OR = 1.85, CI 1.09–3.14). Age, male gender, onset age, and cold area of residency significantly influenced anti-JCV antibody sera positivity. Only age of onset and cold area of residency were related to the index. No significant difference was observed between type, dosage, and duration of previous immunosuppressant drugs and anti-JCV antibody positivity and index value. © 2018, Journal of NeuroVirology, Inc.